Logo

AstraZeneca Provides Update on P-III (AMPLIFY) Trial of Calquence for Treating Chronic Lymphocytic Leukemia

Share this
AstraZeneca

AstraZeneca Provides Update on P-III (AMPLIFY) Trial of Calquence for Treating Chronic Lymphocytic Leukemia

Shots:

  • The P-III (AMPLIFY) study is assessing the safety & efficacy of Calquence (BTK inhibitor) + venetoclax, with/without obinutuzumab, vs SoC chemoimmunotherapy in treatment-naïve CLL adults without del(17p) or TP53 mutation 
  • Interim analysis of the study depicted improved PFS and immature OS data, though a favorable trend towards the combination was observed, its evaluation is underway9
  • Safety profile & tolerability aligned with the known safety outcomes without any new concerns; low cardiac toxicity was seen. Data will be highlighted at future conferences and shared with regulatory bodies worldwide

Ref: AstraZeneca | Image: AstraZeneca 

Related News:- AstraZeneca Showcases the P-III (ECHO) Study Data of Calquence Combination Regimen for Mantle Cell Lymphoma at EHA 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions